NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/02/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,436.31 mln
Float52.06 mln
Earnings Date08/06/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
78.00
Transformational upside
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
0.15
Very low leverage
ROE
-73.60
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Vera Therapeutics is a California-based biotechnology company working to develop new medicines for patients living with immune system disorders and autoimmune kidney diseases. Its leading drug candidate, atacicept, targets two proteins that drive harmful immune responses and can be self-injected by patients at home, with ongoing studies focused on IgA nephropathy. The company is also advancing two additional treatments: MAU868, an antibody designed to fight BK virus infections, and VT-109, a next-generation molecule aimed at a broader range of autoimmune conditions. Founded in 2016 and headquartered in Brisbane, California, Vera Therapeutics was previously known as Trucode Gene Repair before adopting its current name in 2020.
